Cardiac Biomarkers Market

Cardiac Biomarkers Market by Types (Troponin, Creatine kinase - MB, Natriuretic peptides - B-type Natriuretic Peptide & N-terminal pro B-type Natriuretic Peptide, Myoglobin, Ischemia Modified Albumin (IMA), Heart-type Fatty Acid Binding Protein, and LDH Isoenzymes), Applications (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Cardiomyopathy, Ischemia, Myocarditis, and Atrial Fibrillation), End-users (Laboratory Testing and Point of Care (POC) Testing), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1009
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 141
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global cardiac biomarkers market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of cardiovascular diseases and increasing number of the geriatric population globally.

Cardiac biomarkers are types of proteins, which are released into the bloodstream from heart muscle. The biomarkers are released when the heart muscle is damaged due to a blocked artery. Cardiac biomarkers, as endogenous agents such as carbohydrates, hormones, and proteins, are released into the blood when the heart is weakened or nervous. They are mainly used to diagnose heart attacks, acute coronary syndrome (ACS), and other disorders including a lack of blood supply to the heart.

Troponin is one of the most widely adopted biomarkers for detecting heart injury among cardiac biomarker tests and troponin levels rise quickly after heart injury and remain up for up to two weeks. The test is done using a blood sample drawn from a vein in the hand or arm with a needle. The test, which takes several hours to complete, helps in the diagnosis of a heart attack. Cardiac biomarkers are used to stratify risk for a variety of cardiovascular disorders (CVDs) such as myocardial infraction, congestive heart failure, and acute coronary syndrome (ACS). CK-MB, troponin I and T, myoglobin, BNPs, IMA, and other cardiac biomarkers are commonly used in an integrated diagnostic approach for CVDs.

Global Cardiac Biomarkers Market Summary

Market Trends, Drivers, Restraints, and Opportunities

  • High accuracy, economic price, quick outcomes are some of the features of cardiac point of care (POC) testing. These factors are projected to boost the market growth during the forecast period.
  • Increasing number of patients with diseases such as hypertension, dyslipidemia obesity, and diabetes, which poise major risk factors for cardiovascular disorders, are projected to propel the market growth.
  • Increasing number of COVID-19 cases has affected the market as there has been a sharp decreased in the number of patients with cardiovascular disorders to opt for diagnosis. This is expected to hamper the market growth.
  • Availability of other diagnostic methods for cardiovascular diseases and possibility of side effects of using biomarkers are major factors that can hamper the market growth.
  • Increased R&D funding from public as well as private organizations is projected to create lucrative opportunities for the market players.

Scope of the Report

The report on the global cardiac biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Cardiac Biomarkers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Troponin, Creatine kinase - MB, Natriuretic Peptides - B-type Natriuretic Peptide & N-terminal pro B-type Natriuretic Peptide, Myoglobin, Ischemia Modified Albumin, Heart-type Fatty Acid Binding Protein, and LDH Isoenzymes), Applications (Acute Coronary Syndrome, Myocardial infarction, Congestive Heart Failure, Cardiomyopathy, Ischemia, Myocarditis, and Atrial Fibrillation), and End-users (Laboratory Testing and Point of Care Testing)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd.

 

Market Segment Insights

Troponin segment is expected to constitute a key share of the market
Based on types, the cardiac biomarkers market is segmented into troponin, creatine kinase - mb (CK-MB), natriuretic peptides - b-type natriuretic peptide (BNP) & n-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, ischemia modified albumin (IMA), heart-type fatty acid binding protein (H-FABP), LDH isoenzymes. The troponin segment is expected to constitute a key share of the market during the forecast period owing to their benefits in detecting AMI and their effectiveness in diagnosing cardiovascular diseases in a timely and reliable manner compared to other tests, which help in preventing adverse cardiac events. On the other hand, the natriuretic peptides segment is anticipated to expand at a rapid pace during the forecast period due to its efficiency in accurately diagnosing CHF.

Global Cardiac Biomarkers Market By Type

Acute coronary syndrome segment is expected to hold a major market share
On the basis of applications, the market is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, cardiomyopathy, ischemia, myocarditis, and atrial fibrillation. The acute coronary syndrome segment is expected to hold a major share of the market during the forecast period owing to a high rate of acute coronary syndrome. On the other hand, the myocardial infarction segment is anticipated to expand at a rapid pace during the forecast period owing to increasing geriatric population the prevalence of an obese & sedentary lifestyle among individuals, smoking & alcohol intake, and unhealthy eating patterns, all of which eventually contribute to obesity.

Point of care segment is expected to expand at a rapid pace
Based on end-users, the cardiac biomarkers market is bifurcated into laboratory testing and point of care (POC) testing. The POC testing segment is expected to account for a key share of the market during the forecast period owing to increasing demand for POC test kits. These kits are compact and convenient as they are easy to use, making them as common medical equipment in the home healthcare segment.

Global Cardiac Biomarkers Market By End-User

North America is anticipated to dominate the market
In terms of regions, the cardiac biomarkers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to the high prevalence of coronary heart disease in the region as well as the wide popularity of point-of-care diagnostics, which have resulted in a substantial disease burden.

On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing population and rising prevalence of cardiovascular diseases in this region. The advent of the cardiac biomarkers vertical in the region is expected to be fueled by this rapid development.

Global Cardiac Biomarkers Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Cardiac Biomarkers Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Cardiac Biomarkers Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Cardiac Biomarkers Market - Supply Chain
  4.5. Global Cardiac Biomarkers Market Forecast
     4.5.1. Cardiac Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Cardiac Biomarkers Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Cardiac Biomarkers Market Absolute $ Opportunity
5. Global Cardiac Biomarkers Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Cardiac Biomarkers Market Size and Volume Forecast by Types
     5.3.1. Troponin
     5.3.2. Creatine Kinase - MB (CK-MB)
     5.3.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
     5.3.4. Myoglobin
     5.3.5. Ischemia Modified Albumin (IMA)
     5.3.6. Heart-Type Fatty Acid Binding Protein
     5.3.7. LDH Isoenzymes
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cardiac Biomarkers Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Cardiac Biomarkers Market Size and Volume Forecast by Applications
     6.3.1. Acute Coronary Syndrome
     6.3.2. Myocardial Infarction
     6.3.3. Congestive Heart Failure
     6.3.4. Cardiomyopathy
     6.3.5. Ischemia
     6.3.6. Myocarditis
     6.3.7. Atrial Fibrillation
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Cardiac Biomarkers Market Analysis and Forecast by End Users
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by End Users
     7.2.2. Y-o-Y Growth Projections by End Users
  7.3. Cardiac Biomarkers Market Size and Volume Forecast by End Users
     7.3.1. Laboratory Testing
     7.3.2. Point of Care Testing
  7.4. Absolute $ Opportunity Assessment by End Users
  7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Cardiac Biomarkers Market Analysis and Forecast by Region
  8.1. Market Trends
  8.2. Introduction
     8.2.1. Basis Point Share (BPS) Analysis by Region
     8.2.2. Y-o-Y Growth Projections by Region
  8.3. Cardiac Biomarkers Market Size and Volume Forecast by Region
     8.3.1. North America
     8.3.2. Latin America
     8.3.3. Europe
     8.3.4. Asia Pacific
     8.3.5. Middle East and Africa (MEA)
  8.4. Absolute $ Opportunity Assessment by Region
  8.5. Market Attractiveness/Growth Potential Analysis by Region
  8.6. Global Cardiac Biomarkers Demand Share Forecast, 2019-2026
9. North America Cardiac Biomarkers Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
  9.2. North America Cardiac Biomarkers Market Size and Volume Forecast by Country
     9.2.1. U.S.
     9.2.2. Canada
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. North America Cardiac Biomarkers Market Size and Volume Forecast by Types
     9.4.1. Troponin
     9.4.2. Creatine Kinase - MB (CK-MB)
     9.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
     9.4.4. Myoglobin
     9.4.5. Ischemia Modified Albumin (IMA)
     9.4.6. Heart-Type Fatty Acid Binding Protein
     9.4.7. LDH Isoenzymes
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. North America Cardiac Biomarkers Market Size and Volume Forecast by Applications
     9.7.1. Acute Coronary Syndrome
     9.7.2. Myocardial Infarction
     9.7.3. Congestive Heart Failure
     9.7.4. Cardiomyopathy
     9.7.5. Ischemia
     9.7.6. Myocarditis
     9.7.7. Atrial Fibrillation
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. North America Cardiac Biomarkers Market Size and Volume Forecast by End Users
     9.10.1. Laboratory Testing
     9.10.2. Point of Care Testing
  9.11. Basis Point Share (BPS) Analysis by End Users
  9.12. Y-o-Y Growth Projections by End Users
  9.13. Market Attractiveness/Growth Potential Analysis
     9.13.1. By Country
     9.13.2. By Product Type
     9.13.3. By Application
  9.14. North America Cardiac Biomarkers Demand Share Forecast, 2019-2026
10. Latin America Cardiac Biomarkers Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Latin America Average Pricing Analysis
  10.2. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
  10.4. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Types
     10.4.1. Troponin
     10.4.2. Creatine Kinase - MB (CK-MB)
     10.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
     10.4.4. Myoglobin
     10.4.5. Ischemia Modified Albumin (IMA)
     10.4.6. Heart-Type Fatty Acid Binding Protein
     10.4.7. LDH Isoenzymes
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Latin America Cardiac Biomarkers Market Size and Volume Forecast by Applications
     10.7.1. Acute Coronary Syndrome
     10.7.2. Myocardial Infarction
     10.7.3. Congestive Heart Failure
     10.7.4. Cardiomyopathy
     10.7.5. Ischemia
     10.7.6. Myocarditis
     10.7.7. Atrial Fibrillation
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Latin America Cardiac Biomarkers Market Size and Volume Forecast by End Users
     10.10.1. Laboratory Testing
     10.10.2. Point of Care Testing
  10.11. Basis Point Share (BPS) Analysis by End Users
  10.12. Y-o-Y Growth Projections by End Users
  10.13. Market Attractiveness/Growth Potential Analysis
     10.13.1. By Country
     10.13.2. By Product Type
     10.13.3. By Application
  10.14. Latin America Cardiac Biomarkers Demand Share Forecast, 2019-2026
11. Europe Cardiac Biomarkers Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Europe Average Pricing Analysis
  11.2. Europe Cardiac Biomarkers Market Size and Volume Forecast by Country
     11.2.1. Germany
     11.2.2. France
     11.2.3. Italy
     11.2.4. U.K.
     11.2.5. Spain
     11.2.6. Russia
     11.2.7. Rest of Europe
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Europe Cardiac Biomarkers Market Size and Volume Forecast by Types
     11.4.1. Troponin
     11.4.2. Creatine Kinase - MB (CK-MB)
     11.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
     11.4.4. Myoglobin
     11.4.5. Ischemia Modified Albumin (IMA)
     11.4.6. Heart-Type Fatty Acid Binding Protein
     11.4.7. LDH Isoenzymes
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Europe Cardiac Biomarkers Market Size and Volume Forecast by Applications
     11.7.1. Acute Coronary Syndrome
     11.7.2. Myocardial Infarction
     11.7.3. Congestive Heart Failure
     11.7.4. Cardiomyopathy
     11.7.5. Ischemia
     11.7.6. Myocarditis
     11.7.7. Atrial Fibrillation
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Europe Cardiac Biomarkers Market Size and Volume Forecast by End Users
     11.10.1. Laboratory Testing
     11.10.2. Point of Care Testing
  11.11. Basis Point Share (BPS) Analysis by End Users
  11.12. Y-o-Y Growth Projections by End Users
  11.13. Market Attractiveness/Growth Potential Analysis
     11.13.1. By Country
     11.13.2. By Product Type
     11.13.3. By Application
  11.14. Europe Cardiac Biomarkers Demand Share Forecast, 2019-2026
12. Asia Pacific Cardiac Biomarkers Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Asia Pacific Average Pricing Analysis
  12.2. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Country
     12.2.1. China
     12.2.2. Japan
     12.2.3. South Korea
     12.2.4. India
     12.2.5. Australia
     12.2.6. Rest of Asia Pacific (APAC)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Types
     12.4.1. Troponin
     12.4.2. Creatine Kinase - MB (CK-MB)
     12.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
     12.4.4. Myoglobin
     12.4.5. Ischemia Modified Albumin (IMA)
     12.4.6. Heart-Type Fatty Acid Binding Protein
     12.4.7. LDH Isoenzymes
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by Applications
     12.7.1. Acute Coronary Syndrome
     12.7.2. Myocardial Infarction
     12.7.3. Congestive Heart Failure
     12.7.4. Cardiomyopathy
     12.7.5. Ischemia
     12.7.6. Myocarditis
     12.7.7. Atrial Fibrillation
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Asia Pacific Cardiac Biomarkers Market Size and Volume Forecast by End Users
     12.10.1. Laboratory Testing
     12.10.2. Point of Care Testing
  12.11. Basis Point Share (BPS) Analysis by End Users
  12.12. Y-o-Y Growth Projections by End Users
  12.13. Market Attractiveness/Growth Potential Analysis
     12.13.1. By Country
     12.13.2. By Product Type
     12.13.3. By Application
  12.14. Asia Pacific Cardiac Biomarkers Demand Share Forecast, 2019-2026
13. Middle East & Africa Cardiac Biomarkers Market Analysis and Forecast
  13.1. Introduction
     13.1.1. Basis Point Share (BPS) Analysis by Country
     13.1.2. Y-o-Y Growth Projections by Country
     13.1.3. Middle East & Africa Average Pricing Analysis
  13.2. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Country
     13.2.1. Saudi Arabia
     13.2.2. South Africa
     13.2.3. UAE
     13.2.4. Rest of Middle East & Africa (MEA)
  13.3. Absolute $ Opportunity Assessment by Country
  13.4. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Types
     13.4.1. Troponin
     13.4.2. Creatine Kinase - MB (CK-MB)
     13.4.3. Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
     13.4.4. Myoglobin
     13.4.5. Ischemia Modified Albumin (IMA)
     13.4.6. Heart-Type Fatty Acid Binding Protein
     13.4.7. LDH Isoenzymes
  13.5. Basis Point Share (BPS) Analysis by Types
  13.6. Y-o-Y Growth Projections by Types
  13.7. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by Applications
     13.7.1. Acute Coronary Syndrome
     13.7.2. Myocardial Infarction
     13.7.3. Congestive Heart Failure
     13.7.4. Cardiomyopathy
     13.7.5. Ischemia
     13.7.6. Myocarditis
     13.7.7. Atrial Fibrillation
  13.8. Basis Point Share (BPS) Analysis by Applications
  13.9. Y-o-Y Growth Projections by Applications
  13.10. Middle East & Africa Cardiac Biomarkers Market Size and Volume Forecast by End Users
     13.10.1. Laboratory Testing
     13.10.2. Point of Care Testing
  13.11. Basis Point Share (BPS) Analysis by End Users
  13.12. Y-o-Y Growth Projections by End Users
  13.13. Market Attractiveness/Growth Potential Analysis
     13.13.1. By Country
     13.13.2. By Product Type
     13.13.3. By Application
  13.14. Middle East & Africa Cardiac Biomarkers Demand Share Forecast, 2019-2026
14. Competition Landscape
  14.1. Global Cardiac Biomarkers Market: Market Share Analysis
  14.2. Cardiac Biomarkers Distributors and Customers
  14.3. Cardiac Biomarkers Market: Competitive Dashboard
  14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     14.4.1. Alere, Inc.,
     14.4.2. Siemens Healthcare GmbH
     14.4.3. Roche Diagnostics
     14.4.4. Beckman Coulter, Inc.
     14.4.5. Thermo Fisher Scientific, Inc.
     14.4.6. Becton, Dickinson and Company
     14.4.7. bioMérieux SA
     14.4.8. Bio-R
Segments Covered in the Report
The global cardiac biomarkers market has been segmented on the basis of

Types
  • Troponin
  • Creatine Kinase - MB (CK-MB)
  • Natriuretic Peptides - B-Type Natriuretic Peptide (BNP) & N-Terminal Pro B-Type Natriuretic Peptide
  • Myoglobin
  • Ischemia Modified Albumin (IMA)
  • Heart-Type Fatty Acid Binding Protein
  • LDH Isoenzymes
Applications
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Cardiomyopathy
  • Ischemia
  • Myocarditis
  • Atrial Fibrillation
End-users
  • Laboratory Testing
  • Point of Care Testing
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Alere, Inc.,
  • Siemens Healthcare GmbH
  • Roche Diagnostics
  • Beckman Coulter, Inc.
  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Randox Laboratories Ltd.

Key players competing in the cardiac biomarkers market are Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., and Randox Laboratories Ltd.

These companies are constantly focusing on generating growth by creating innovative product designs and new tests as well as improving the specificity of the tests. Alere, Inc., for example, made the Alere triage line, which combines three important biomarkers: CK-MB, myoglobin, and troponin I. This test is easy to use and popular since it is a hybrid tool and an effective point-of-care cardiac testing package.

Global Cardiac Biomarkers Market By Key Players

Buy Report